D

Deutetrabenazine

Efrain Antonio Gonzalez
Department of Psychiatry and Behavioral
Sciences, University of Miami Leonard M. Miller
School of Medicine, Miami, FL, USA

Generic Name

Deutetrabenazine

Brand Name

Austedo

Class

Central Monoamine-Depleting Agents

Proposed Mechanism(s) of Action

Oral vesicular monoamine transporter-2 (VMAT-2) inhibitor; decreased uptake of monoamines (dopamine, norepinephrine, serotonin, histamine) into synaptic vesicles and reversible depletion of monoamine stores from nerve terminals.

Indication

Treatment of chorea associated with Huntington's disease.

Treatment of Tardive Dyskinesia.

Off Label Use

No common off label use

Side Effects

Serious

Akathisia, agitation, restlessness, parkinsonism, and increased risk of depression and suicidal ideation in patients with Huntington disease, may prolong Q-T interval.

Common

Somnolence, fatigue, depression, dry mouth, urinary tract infection, insomnia, anxiety, bruising, constipation, dizziness, imbalance, contusion.

References and Readings

Free Drug Online and PDA Software. www.epocrates.com.
Free Drug Online and PDA Software. www.medscape.com.
Schmidt, C. (2017). First deuterated drug approved. *Nature Biotechnology*, 35(6), 493.